Payment overview · 2025
General Payments
$225.06
12 reported records · 6 companies
Healthcare provider profile · identity verified
Marty Jacob, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BOYNTON BEACH, FL · NPI 1851336028
Verified facts
What the public records show
CMS Open Payments records show Marty Jacob, MD received $225.06 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 37.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $85.36 | 37.9% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $49.72 | 22.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.42 | 10.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.17 | 10.3% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.87 | 9.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.52 | 9.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $225.06 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $67.38 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $67.38 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.99 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.99 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 423 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 422 | 118 |
| Atorvastatin Calcium | Atorvastatin Calcium | 410 | 106 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 319 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 273 | 76 |
| Losartan Potassium | Losartan Potassium | 267 | 74 |
| Eliquis | Apixaban | 240 | 32 |
| Simvastatin | Simvastatin | 193 | 48 |
| Metformin Hcl | Metformin Hcl | 190 | 50 |
| Gabapentin | Gabapentin | 171 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 146 | 34 |
| Alprazolam | Alprazolam | 134 | 28 |
| Omeprazole | Omeprazole | 134 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 40 |
| Furosemide | Furosemide | 120 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 22 |
| Allopurinol | Allopurinol | 111 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 107 | 31 |
| Donepezil Hcl | Donepezil Hcl | 103 | 14 |
| Trazodone Hcl | Trazodone Hcl | 93 | 28 |
| Lisinopril | Lisinopril | 87 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 83 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 17 |
| Mirtazapine | Mirtazapine | 73 | 17 |
| Carvedilol | Carvedilol | 72 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 13 |
| Famotidine | Famotidine | 65 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 26 |
| Xarelto | Rivaroxaban | 62 | 13 |
| Atenolol | Atenolol | 61 | 14 |
| Entresto | Sacubitril/Valsartan | 61 | suppressed |
| Azithromycin | Azithromycin | 57 | 49 |
| Sertraline Hcl | Sertraline Hcl | 57 | 16 |
| Glimepiride | Glimepiride | 55 | 11 |
| Ezetimibe | Ezetimibe | 54 | 19 |
| Levetiracetam | Levetiracetam | 51 | 11 |
| Potassium Chloride | Potassium Chloride | 51 | 21 |
| Terazosin Hcl | Terazosin Hcl | 51 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | suppressed |
| Finasteride | Finasteride | 46 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 46 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | suppressed |
| Memantine Hcl | Memantine Hcl | 45 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 41 | suppressed |
| Baclofen | Baclofen | 40 | suppressed |
| Lovastatin | Lovastatin | 40 | 11 |
| Valsartan | Valsartan | 39 | suppressed |
| Fenofibrate | Fenofibrate | 38 | 13 |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Bumetanide | Bumetanide | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Diazepam | Diazepam | 35 | 12 |
| Carbamazepine | Carbamazepine | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Temazepam | Temazepam | 34 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 32 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Prednisone | Prednisone | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Multaq | Dronedarone Hcl | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 17 |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Permethrin | Permethrin | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 18 |
| Risperidone | Risperidone | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Movantik | Naloxegol Oxalate | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 11 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Acetic Acid | Acetic Acid | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Clozapine | Clozapine | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $225.06 · 12 records | Novo Nordisk Inc | Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, JARDIANCE, OTEZLA, Ozempic, PROLIA, REPATHA, Rybelsus, TZIELD, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error